These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12742411

  • 21. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.
    Transplantation; 1998 Oct 27; 66(8):1047-52. PubMed ID: 9808490
    [Abstract] [Full Text] [Related]

  • 22. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 23. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
    Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR.
    J Heart Lung Transplant; 2002 May 27; 21(5):547-54. PubMed ID: 11983544
    [Abstract] [Full Text] [Related]

  • 24. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW.
    Transplantation; 2003 Nov 15; 76(9):1289-93. PubMed ID: 14627905
    [Abstract] [Full Text] [Related]

  • 25. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb 15; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 26. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
    Kim JM, Lee SK, Kim SJ, Joh JW, Kwon CH, Choe YH, Shin M, Kim EY, Moon JI, Jung GO, Choi GS.
    Transplant Proc; 2010 Apr 15; 42(3):895-9. PubMed ID: 20430199
    [Abstract] [Full Text] [Related]

  • 27. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC.
    Transplantation; 2004 Jul 27; 78(2):205-10. PubMed ID: 15280679
    [Abstract] [Full Text] [Related]

  • 28. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota.
    Wudhikarn K, Holman CJ, Linan M, Blaes AH, Dunitz JM, Hertz ME, Peterson BA.
    Clin Transplant; 2011 Jul 27; 25(5):705-13. PubMed ID: 21077949
    [Abstract] [Full Text] [Related]

  • 29. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T, Zwick DL, Rothberg PG, Warady BA.
    Pediatr Nephrol; 1999 Nov 27; 13(9):748-54. PubMed ID: 10603113
    [Abstract] [Full Text] [Related]

  • 30. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 31. Development of lymphoproliferative disease after liver transplantation.
    Marqués E, Jiménez C, Manrique A, Vallejo GH, Clemares M, Ortega P, Moreno E.
    Transplant Proc; 2008 Nov 15; 40(9):2988-9. PubMed ID: 19010169
    [Abstract] [Full Text] [Related]

  • 32. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS.
    J Pediatr Surg; 2008 Dec 15; 43(12):2174-7. PubMed ID: 19040929
    [Abstract] [Full Text] [Related]

  • 33. Posttransplantation lymphoproliferative disorder: manifestations in pediatric thoracic organ recipients.
    Lim GY, Newman B, Kurland G, Webber SA.
    Radiology; 2002 Mar 15; 222(3):699-708. PubMed ID: 11867788
    [Abstract] [Full Text] [Related]

  • 34. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F, Kunitake H, Laks H, Odim J.
    Pediatr Transplant; 2006 Feb 15; 10(1):60-6. PubMed ID: 16499589
    [Abstract] [Full Text] [Related]

  • 35. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V.
    Clin Transplant; 1996 Jun 15; 10(3):248-55. PubMed ID: 8826661
    [Abstract] [Full Text] [Related]

  • 36. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep 15; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 37. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov 15; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 38. Azathioprine withdrawal in stable lung and heart/lung recipients receiving cyclosporine-based immunosuppression.
    Hoffmeyer F, Hoeper MM, Spiekerkötter E, Harringer W, Haverich A, Fabel H, Niedermeyer J.
    Transplantation; 2000 Aug 15; 70(3):522-5. PubMed ID: 10949197
    [Abstract] [Full Text] [Related]

  • 39. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review.
    Marks WH, Ilsley JN, Dharnidharka VR.
    Transplant Proc; 2011 Jun 15; 43(5):1395-404. PubMed ID: 21693205
    [Abstract] [Full Text] [Related]

  • 40. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders.
    Peraira JR, Segovia J, Fuertes B, Fernández JA, Escudier JM, Salas C, Pulpón LA.
    Transplant Proc; 2003 Aug 15; 35(5):2009-10. PubMed ID: 12962879
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.